SCHEMBL17895203

SCHEMBL17895203

N#Cc1ccc2nc(NCCCCCCN)c3ncc(-c4ccc(O)c(O)c4)n3c2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 9/20 0.42
CHUK O15111 8/20 0.42
CDK11B P21127 2/20 0.42
CDK7 P50613 2/20 0.42
CDK13 Q14004 2/20 0.42
MAP3K19 Q56UN5 2/20 0.42
MYLK4 Q86YV6 2/20 0.42
CDK11A Q9UQ88 2/20 0.42
ERN1 O75460 1/20 0.42
RPS6KA4 O75676 1/20 0.42
PRKD3 O94806 1/20 0.42
CDK1 P06493 1/20 0.42
KIT P10721 1/20 0.42
CDK2 P24941 1/20 0.42
TYK2 P29597 1/20 0.42
CSNK1D P48730 1/20 0.42
CDK9 P50750 1/20 0.42
LIMK1 P53667 1/20 0.42
CDK16 Q00536 1/20 0.42
MAPK7 Q13164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17895212 0.96 IKBKB (0.43) IKBKBCHUKCDK11BCDK7CDK13
SCHEMBL17895207 0.93 BRD4 (0.41) IKBKBCHUKCDK11BCDK7CDK13
SCHEMBL17895190 0.93 IKBKB (0.49) IKBKBCHUKCDK11BCDK7CDK13
SCHEMBL17895271 0.89 BRD4 (0.38) IKBKBCHUKCDK11BCDK7CDK13
SCHEMBL17894992 0.88 IKBKB (0.44) IKBKBCHUKCDK11BCDK7CDK13
SCHEMBL17895072 0.86 BRD4 (0.49) IKBKBCHUKCDK11BCDK7CDK13
SCHEMBL17895062 0.85 IKBKB (0.42) IKBKBCHUKCDK11BCDK7CDK13
SCHEMBL17894995 0.85 IKBKB (0.43) IKBKBCHUKCDK11BCDK7CDK13
SCHEMBL17895303 0.85 IKBKB (0.43) IKBKBCHUKCDK11BCDK7CDK13
SCHEMBL17895310 0.84 IKBKB (0.45) IKBKBCHUKCDK11BCDK7CDK13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3240789-B1 NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER UNIV MONTPELLIER (FR) 2020-07-29 EP claimed
EP-3240789-A1 NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER Université de Montpellier (FR) 2017-11-08 EP claimed
WO-2016107895-A1 NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER UNIVERSITE DE MONTPELLIER (FR) 2016-07-07 WO claimed
EP-3240789-B1 NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER UNIV MONTPELLIER (FR) 2020-07-29 EP disclosed
US-10689384-B2 Imidazo[1,2-a]quinoxalines and derivatives thereof for the treatment of cancer UNIVERSITE DE MONTPELLIER (FR) 2020-06-23 US disclosed
EP-3240789-A1 NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER Université de Montpellier (FR) 2017-11-08 EP disclosed
WO-2016107895-A1 NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER UNIVERSITE DE MONTPELLIER (FR) 2016-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10689384-B2 Imidazo[1,2-a]quinoxalines and derivatives thereof for the treatment of cancer NQO1, NQO2, ABL1 IKBKB 1832/4885CHUK 1133/4885CDK11B 596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.